echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first domestic MET inhibitor "Volitini" listing application was sponsored by CDE.

    The first domestic MET inhibitor "Volitini" listing application was sponsored by CDE.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    This application for a new drug is based on an open-label Phase II Registration Data Support (NCT02897479).
    the latest data, presented at the 2020 ASCO Conference, included 70 cases of MET14-mutant non-small cell lung cancer, of which 57.1% were lung adenocarcinoma, up to 35.7% were lung sarcoma -like cancer (PSC), and up to 22% combined with brain metastasis.
    phase, 92.9% of patients were in stage IV and 60% were treated.
    all patients are treated with volitinib (600 mg (50 kg or more);
    the main research endpoint is ORR.
    results showed that in 61 patients with an evaluative efficacy, the overall effectiveness rate was 47.5% and the disease control rate was 93.4%.
    median PFS is 6.8 months (first in a combined high proportion of PSC patients, the overall PFS is more than half a year). the most common adverse reactions
    included peripheral edema, nausea, elevated AST/ALT levels, vomiting, and low proteinuria.
    the met14 exoon jump mutation in the abnormal lyson-driven gene of lung cancer, the incidence rate in lung adenocarcinoma is 3% to 4%, MET gene mutation is the cause of drug resistance in many tumors, usually met14 exoon jump mutation of lung cancer patients with poor prognosis.
    patients carrying this mutation are insensitive to chemotherapy and treatment is not ideal.
    and lung sarcoma-like cancer (PSC) is a rare type of lung cancer with a very poor prognosis, psC is more prone to invasion and metastasis than other NSCLCs, and met Exon14 plus in PSC can be as high as 31.8 percent, the emergence of Volitinib brings new hope to such patients, we hope that the drug can be approved early, for this type of patient syllitas.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.